The Prevalence and Implications of Factor V rs6687813 Mutation among COVID-19 Patients on D-dimer Levels

Walid Aburayyan

doi:10.35516/jjps.v18i4.2652

المؤلفون

Walid Aburayyan Al-Balqa Applied University, Faculty of Science, Department of Laboratory Analysis

DOI:

https://doi.org/10.35516/jjps.v18i4.2652

الملخص

اجتاح فيروس كوفيد-19 المجتمع البشري في جميع أنحاء العالم، مهددًا الصحة العامة والاقتصاد العالمي. وقد أثارت البيانات المُربكة حول آلية تطور المرض نظريات تنبؤية تتعلق بآثار البيانات الديموغرافية والتنوع الجيني لتشخيص المرض. شارك في الدراسة الحالية 120 مشاركًا؛ 68 ذكرًا و52 أنثى، تتراوح أعمارهم بين 15 و82 عامًا، من بينهم 90 مريضًا مصابًا بكوفيد-19، و30 مشاركًا سليمًا. تم سحب عينات دم من 120 مشاركًا، ثم تم تحليلها لمستويات دي-دايمرباستخدام مقايسة المناعة الفلورية. تم تضخيم عينات الحمض النووي الـ 120 المستخرجة بواسطة تفاعل البوليميراز المتسلسل (PCR) باستخدام بادئات خاصة بالعامل الخامس. تم تسلسل نواتج تفاعل البوليميراز المتسلسل (PCR) وفحصها للكشف عن الطفرات المحتملة في جين العامل الخامس. وُجد معدل طفرة مرتفع بشكل ملحوظ في العامل الخامس (rs6687813) بنسبة 82%، قيمة P<0.001 في عينة الدراسة. وارتبطت الطفرات بشكل ملحوظ بمستويات عالية للغاية من دي-دايمر، بلغت 2975 نانوغرام/مل، مقابل 986 نانوغرام/مل في النوع البري (r=0.228، قيمة P<0.012). أظهر مرضى كوفيد-19 المنومون في المستشفيات مستويات أعلى بكثير من دي-دايمر، مقارنةً بالمرضى غير المنومين، حيث بلغت 3353 نانوغرام/مل مقابل 513 نانوغرام/مل، قيمة P<0.001، على التوالي. وكان معدل احتمال الإصابة بعدوى كوفيد-19 للعمر 1.12، حيث كان من تزيد أعمارهم عن 35 عامًا أكثر عرضة للإصابة بالعدوى من الفئات العمرية الأصغر (r=0.21، قيمة P<0.022). في الختام، تُقدم الدراسة أدلة قوية على الارتباط المباشر بين طفرة العامل الخامس وارتفاع مستويات دي-دايمر لدى مرضى كوفيد-19، ويُوصى بتطبيق اختبار طفرة العامل الخامس كعلامة تشخيصية لمرضى كوفيد-19.

المراجع

YAO, Y., J. CAO, Q. WANG, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. Journal of intensive care, 2020. 8: p. 1-11.

SONI, M., R. GOPALAKRISHNAN, R. VAISHYA, et al. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020. 14(6): p. 2245-2249.

IBA, T., J.H. LEVY, M. LEVI, et al. Coagulopathy in COVID‐19. Journal of Thrombosis and Haemostasis, 2020. 18(9): p. 2103-2109.

HAEMATOLOGY, T.L. COVID-19 coagulopathy: an evolving story. The Lancet. Haematology, 2020. 7(6): p. e425.

RAYYAN, W.A., W.A. HAZZAA, and N. SEDER. The Implications of COVID-19 Infection on Hematologic Parameters and Coagulation Activity: A Review. Biomedical & Pharmacology Journal, 2022. 15(4): p. 1837-1851.

SUGHAYER, M.A., A. MANSOUR, A. AL NUIRAT, et al. Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic. International Journal of Infectious Diseases, 2021. 107: p. 116-120.

UITTE DE WILLIGE, S., M.C. DE VISSER, J.J. HOUWING-DUISTERMAAT, et al. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen γ′ levels. Blood, 2005. 106(13): p. 4176-4183.

JOHNSON, S.E., E. PAI, A. VOROBA, et al. Examining d-dimer and empiric anti-coagulation in covid-19-related thrombosis. Cureus, 2022. 14(7)

FARASANI, A. Biochemical role of serum ferratin and d-dimer parameters in COVID 19 diagnosis. Saudi journal of biological sciences, 2021. 28(12): p. 7486-7490.

TANG, N., D. LI, X. WANG, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis, 2020. 18(4): p. 844-847.

GODIER, A., D. CLAUSSE, S. MESLIN, et al. Major bleeding complications in critically ill patients with COVID-19 pneumonia. Journal of thrombosis and thrombolysis, 2021. 52: p. 18-21.

ZHU, J., J. PANG, P. JI, et al. Elevated interleukin‐6 is associated with severity of COVID‐19: a meta‐analysis. Journal of medical virology, 2021. 93(1): p. 35.

BOSSO, M., T.A. THANARAJ, M. ABU-FARHA, et al. The two faces of ACE2: the role of ACE2 receptor and its polymorphisms in hypertension and COVID-19. Molecular Therapy-Methods & Clinical Development, 2020. 18: p. 321-327.

RAYYAN, W.A. Seroprevalence of SARS-CoV-2 antibodies among Jordanian citizens: A cross-sectional study of the demographic and clinical factors that ameliorate serum IgG concentration. Journal of Applied Pharmaceutical Science, 2022. 12(11): p. 151-156.

DEME, D., S. KOVACS, and A. TELEKES. Overall survival prediction of advanced cancer patients by selection of the most significant baseline serum biomarker combination. Pathology & Oncology Research, 2022. 28: p. 1610004.

KONSTANTINIDES, S.V., G. MEYER, C. BECATTINI, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). European heart journal, 2020. 41(4): p. 543-603.

SEDER, N., W.A. RAYYAN, M.H. O'LA AL-FAWARES, et al. Pseudomonas aeruginosa Virulence Factors and Antivirulence mechanisms to Combat Drug Resistance; A Systematic Review. Sapporo Medical Journal, 2023. 10: p. 11.

ALBALBAKI MM, AL-FAWARES O, ABURAYYAN W, et al. The correlation of gene mutation of coagulopathy cascade with elevated D-dimer levels in COVID-19 patients. J Appl Pharm Sci. , 2023. 0(0): p. 0. http://doi.org/10.7324/JAPS.2023.145308

YUSUF, M., A. GUPTA, A. KUMAR, et al. Mechanism and pathophysiology of activated protein C-related factor V leiden in venous thrombosis. Asian Journal of Transfusion Science, 2012. 6(1): p. 47.

ABURAYYAN, W.S. High-throughput RNA extraction method for P. aeruginosa and S. pyogenes biofilms. Journal of Applied Pharmaceutical Science, 2023. 13(3): p. 097-105.

SEDER, N., M.H. ABU BAKAR, and W.S. ABU RAYYAN. Transcriptome Analysis of Pseudomonas aeruginosa Biofilm Following the Exposure to Malaysian Stingless Bee Honey. Adv Appl Bioinform Chem, 2021. 14: p. 1-11. 10.2147/AABC.S292143

LIPPI, G., M. PLEBANI, and B.M. HENRY. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clinica chimica acta, 2020. 506: p. 145-148.

EPPENBERGER, D., H. NILIUS, B. ANAGNOSTELIS, et al. Current knowledge on Factor V Leiden mutation as a risk factor for recurrent venous thromboembolism: A systematic review and meta-analysis. Frontiers in cardiovascular medicine, 2022. 9: p. 883986.

ARSOV, T., D. MILADINOVA, and M. SPIROSKI. Factor V Leiden is associated with higher risk of deep venous thrombosis of large blood vessels. Croatian medical journal, 2006. 47(3): p. 433-439.

LEE, S., C.H. LEE, M.S. SEO, et al. Integrative analyses of genes about venous thromboembolism: An umbrella review of systematic reviews and meta-analyses. Medicine, 2022. 101(43)

HAMEDI, B., J. FEULEFACK, A. KHAN, et al. Association between factor V Leiden mutation and recurrent pregnancy loss in the middle east countries: a Newcastle–Ottawa meta-analysis. Archives of Gynecology and Obstetrics, 2020. 302: p. 345-354.

NASIF, W.A., A.S. EL-MOURSY ALI, M. HASAN MUKHTAR, et al. Elucidating the correlation of D-dimer levels with COVID-19 severity: a scoping review. Anemia, 2022. 2022

WANG, H., F.R. ROSENDAAL, M. CUSHMAN, et al. D‐dimer, thrombin generation, and risk of a first venous thrombosis in the elderly. Research and Practice in Thrombosis and Haemostasis, 2021. 5(5): p. e12536.

BIKDELI, B., M.V. MADHAVAN, D. JIMENEZ, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. Journal of the American college of cardiology, 2020. 75(23): p. 2950-2973.

KUMAR, K. and L. AFONSO. Cardiovascular risk prediction in the elderly. Journal of Geriatric Cardiology: JGC, 2019. 16(5): p. 414.

FAN, B.E., T. UMAPATHI, K. CHUA, et al. Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients. Journal of thrombosis and thrombolysis, 2021. 51: p. 971-977.

STATSENKO, Y., F. AL ZAHMI, T. HABUZA, et al. Impact of age and sex on COVID-19 severity assessed from radiologic and clinical findings. Frontiers in cellular and infection microbiology, 2022. 11: p. 1395.

BRUINE DE BRUIN, W. Age differences in COVID-19 risk perceptions and mental health: Evidence from a national US survey conducted in March 2020. The Journals of Gerontology: Series B, 2021. 76(2): p. e24-e29.

WHO. WHO Coronavirus (COVID-19) Dashboard 2019; Available from: https://covid19.who.int/.

POUDEL, A., Y. POUDEL, A. ADHIKARI, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. Plos one, 2021. 16(8): p. e0256744.

WOLFE, K., M. SIROTA, and A.D. CLARKE. Age differences in COVID-19 risk-taking, and the relationship with risk attitude and numerical ability. Royal Society open science, 2021. 8(9): p. 201445.